SKR is a medical technology platform company and was founded in 2009 by a team of healthcare veterans. The company's vision is to become a leading medical equipment, service and solution provider that makes quality healthcare accessible and affordable to patients in China.
SKR has made three key investments: AMS, Daijia and TCL Healthcare.
AMS is the #1 player in China in the positron radiopharmaceutical industry, with the widest distribution network, and is one of only two companies in China licensed to produce and sell Fluorodeoxy- glucose (F18-FDG) for use in PET/CT scanners. PET/CT scanners are used in oncology, neurology and cardiology and require a radiotracer to be injected into the patient’s body - the most common is FDG-18, which is produced by a cyclotron. In oncology PET/CT scanners are used for detection as well as clinical staging to assess the efficacy of cancer treatment, to change the course of ineffective chemotherapy and to avoid unnecessary diagnostic and therapeutic procedures. AMS also distributes cyclotrons and provides maintenance services for nuclear medicine equipment, enabling the Company to provide total solutions for nuclear medicine departments.
Daijia is a healthcare IT company that engages in research, development, manufacturing, sales, system integration and maintenance services for Health Information Exchange (“HIE”), HIE related applications, Picture Archive Compression Systems (“PACS”) and other healthcare IT solutions. The Company's HIE products include Hospital HIE solutions - which can provide full connectivity across hospital departments, more simplified products that focus on specific departments and business intelligence applications - and Regional HIE solutions - which can connect multiple hospitals in a given region. Daijia is the only healthcare IT company to successfully implement a real-time, interoperable HIE solution at a leading Chinese hospital.
TCL Healthcare is aiming to become one of the leading Chinese diagnostic medical imaging company. Its product portfolio includes Digital X-Ray, Ultrasound, MRI, and CT scanners, spanning all the major imaging modalities. TCL Group is one of the top five consumer electronics companies in China. Founded in 1981 in Guangdong, China, it was the world’s 25th-largest consumer electronics producer, 6th largest television producer worldwide, and China’s largest TV producer. TCL is leveraging its brand, manufacturing and technology platforms, and management resources into building a medical equipment business primarily focused on medical imaging.
Headquarters: Xi’an, Shan Xi
Buchang Pharmaceuticals is one of the leading traditional Chinese medicine (TCM) companies in China. Buchang was founded in 1993 by Mr. Zhao Buchang and his elderst son, Mr. Zhao Tao. Starting as a small TCM drug manufacturer, Buchang has evolved into a sales and marketing powerhouse. The Company has the most extensive sales network amongst its peers in China, covering over 15,000 hospitals and 150,000 drug stores. The Company’s product portfolio consists of in-house developed products, as well as products that it acquired and turned into blockbusters. Buchang’s brand name is widely recognized by physicians and patients throughout China. The Company successfully completed its A-share IPO in November 2016.
China Cord Blood Corp
One of only three companies in China granted an operating permit by the Ministry of Health to provide umbilical cord blood stem cell storage services, China Cord Blood is a leading player in the field of stem cell therapy. Principal activities include providing umbilical cord blood stem cell storage services (collection, testing, processing, medical insurance and cryopreservation), providing cord blood stem cells for clinical applications, and researching and developing numerous cellular therapies.
China Cord Blood Corp was listed on New York Stock Exchange in November 2009 (stock ticker: CO).